Dysport (Abobotulinumtoxin-A)

In short: Dysport is a muscle-nerve blocking injection treatment alternative to Botox that contains Botulinum toxin type A. It is FDA approved (2009), TITCK approved and widely used in Türkiye. It acts faster than Botox and has a wider diffusion area. The dose ratio is different (1:2.5).

Description

Dysport, British-French pharmaceutical company ipsen It is a Botulinum toxin type A (abobotulinumtoxin-A) product developed and produced by. International trade name Dysport; Also known as Azzalure in some markets. It was approved by the FDA in 2009 for glabellar wrinkles; It has been used in Europe since 1991 (as the first BoNT-A product). In Türkiye, it is approved by the Ministry of Health TITCK and is widely used as a Botox alternative in medical aesthetic clinics where Ipsen is distributed.

Although Dysport is in the same family with Botox (onabotulinumtoxin-A) and Xeomin (incobotulinumtoxin-A) in terms of the active ingredient Botulinum toxin type A (BoNT-A), it has significant differences in terms of formulation, unit potency, complex protein structure and injection characteristics. The main difference is Dysport's wider diffusion area (muscle diffusion profile) and faster onset of action.

Active Ingredient and Formulation

Active Ingredient Type: The active ingredient of Dysport is abobotulinumtoxin-A, which falls into the Botulinum toxin type A (BoNT-A) category. At the molecular level, all BoNT-A products (Botox, Dysport, Xeomin, Jeuveau, Daxxify) have the same chain (light chain and heavy chain complex), but their biological behavior differs due to production methodology, purification processes and formulation additives.

Complex Protein Structure: Dysport contains the toxin molecule in powder (lyophilized) form with accessory complex proteins. These proteins (hemagglutinin and non-hemagglutinin) increase the stability of the toxin and accelerate its penetration into muscle tissue after injection. Unlike Xeomin (incobotulinumtoxin-A), it contains Dysport complex protein; For this reason, Dysport's immunogenicity profile (risk of antibody development) is similar to Botox and slightly higher than Xeomin.

Unit Potency: Dysport's Speywood Unit (Dysport U) system is used; This system is different from Botox's Allergan Unit system. Dose conversion approximately 1 Botox Unit ≈ 2.5 Dysport Unit It is widely accepted; However, this ratio is controversial and 1:2 or 1:3 ratios have also been reported in some clinical studies. In general clinical practice, the 1:2.5 conversion is used as standard. This difference requires caution when transferring the clinician's Botox experience to Dysport.

Vial Sizes: Dysport is available in 300 Unit (300U) and 500 Unit (500U) vials. Reconstitution protocol: Typically 2.5 mL of sterile saline is used for 500U, providing a concentration of 200 U/mL or 100 U/0.5 mL (similar to the Allergan protocol).

Excipients: Dysport formulation contains lactose (complexed with albumin), human serum albumin (HSA) and sodium chloride (NaCl). These excipients ensure the stability of the toxin during lyophilization and maintain the osmolarity balance when reconstituted before injection.

Mechanism of Effect

Neuromuscular Blockade—SNARE Complex Cleavage: Dysport (abobotulinumtoxin-A) in nerve endings presynaptic terminalBy penetrating the cells, it cleavages the SNAP-25 (synaptosome-associated protein 25) protein that forms the SNARE complex. This breakdown blocks the release of the neurotransmitter acetylcholine (ACh) into the synaptic cleft. As a result, muscle contractility decreases by 70-80% and the muscle relaxes.

Diffusion Character - Wide Halo Effect: Dysport's complex protein, through acetylcholinesterase inhibition, triggers a local increase of acetylcholine in the muscle area, thereby allowing the toxin to diffuse into a wider area. While this "wide diffusion" profile provides an advantage in application to large muscles (masseter, frontalis, platysma), it carries the risk of undesirable widespread effects in application to sensitive and small areas (orbicularis oculi medial, depressor anguli).

Onset of Effect — Fast Kinetics: Dysport's complex proteins accelerate the penetration of the toxin into the muscle. As a result, compared to Botox (4-7 days), Dysport acts faster: 2-3 days Muscle relaxation begins in 1-2. The full effect occurs in a week. For patients, this provides the advantage that the aesthetic result can be observed in a shorter time.

Synaptic Reformation — Neuroplasticity: After Dysport application, the body creates new synaptic structures (neuromuscular junctions) and blocked ACh receptors become reactivated. This process is completed within 3-4 months; Afterwards, muscle function returns to its previous state. Dysport effectiveness may shift with repeated injections (due to immunoglobulin G antibody development); This situation is called "antibody formation against the toxin".

Indications

FDA Approved (Glabellar Lines): Dysport by FDA moderate to severe glabellar lines (wrinkles between the eyebrows) It was approved for treatment (2009). This indication is the same as Botox.

TITCK Approved Indications in Türkiye: Indications approved by the Turkish Ministry of Health TITCK — Dysport is technically a co-modality of Botox — are generally glabellar lines, forehead lines (frontal) and peripheral eye lines (periocular).

Off-Label Uses (in Clinical Practice): Dysport is also applied (off-label) in clinical practice for the following purposes:

• Crow's feet (lateral canthal lines) — orbicularis oculi injection
• Masseter (corner of the chin) muscle lowering / V-line contouring
• Frontalis (forehead lifter) muscle weakening (for control purposes)
• Bunny lines (nose side surface lines)
• Platysma bands (neck) — "Nefertiti lift"
• Hyperhidrosis (excessive sweating)—underarms, palms
• Bruxism treatment — masseter muscle relaxation
• Gummy smile — depressor labii superioris injection
• Lip flip — low-dose injection into the edge of the upper lip

Dosing and Application

Dosage Calculation - Botox Comparison: If Botox planning has been made in Dysport application, 1:2.5 conversion rule is used. For example:

• Glabellar Botox: 20 Ü → Dysport: 50 Ü (20 × 2.5)
• Crow's feet Botox: 12 units/side → Dysport: 30 units/side
• Forehead Botox: 15 Ü → Dysport: 37.5 Ü ≈ 40 Ü (rounded up)

However, the conversion rate is not exact; The clinical response of some patients may show a 1:2 or 1:3 ratio. Experienced clinicians adjust the dose by titration according to patient response.

Standard Application Technique:

1. Consultation and Preparation: The physician evaluates the patient's facial anatomy, facial expression pattern and expectations. Photo documentation is done.
2. Reconstitution: The lyophilized Dysport 300U or 500U vial is reconstituted with sterile 0.9% NaCl solution. Standard: 500U + 2.5 mL saline = 200 U/mL.
3. Injection Technique: Microdoses are injected into the muscle (intramuscular) using a 30 G or 32 G fine needle. Due to Dysport's broad diffusion profile, it can be injected slightly shallower (intradermal-intramuscular border) than Botox.
4. Injection Points: Standard glabellar protocol (Carruthers 5-point — similar to Botox):
   — Midline glabellar: 10-12 Dysport Ü
   — Left corrugator: 15-20 Dysport Ü
   — Right corrugator: 15-20 Dysport Ü
   — Left lateral: 5-10 Dysport Ü
   — Right lateral: 5-10 Dysport Ü
   Total glabellar: 50-70 Dysport Units (equivalent to Botox 20-28 Units)
5. Termination: After application, the area is lightly pressed. The patient can return to normal activity on the same day.

Dose-Dependent Fine-Tunings: Dysport's wide diffusion profile requires more care in injection site selection. For example, injection of Dysport into the medial area of ​​the orbicularis oculi (inner corner of the eye) carries a greater risk of spread than Botox; Xeomin may be preferred in this region.

Comparison: Dysport vs. Botox vs. Xeomin vs. Jeuveau vs. Daxxify

There are five main BoNT-A products available in Türkiye and international markets. The table below shows the location of Dysport:

BoNT-A Products Comparison Chart (including Dysport)

feature	Botox (Allergan)	Dysport (Ipsen)	Xeomin (Merz)	Jeuveau (Evolus)	Daxxify (Revance)
Active Ingredient	Onabotulinumtoxin A	Abobotulinumtoxin A	Incobotulinumtoxin A	Prabotulinumtoxin A	Daxibotulinumtoxin A
Complex Protein	Yes (hyaluronidase + saline)	Yes (accessory complex)	None (pure neurotoxin)	Yes	Yes (stabilized formulation)
Dose Rate (Botox=1)	1 U	≈2.5 Ü (disputed)	≈1 U	≈1 U	≈1 U
Onset of Effect	4-7 days	2-3 days (fast)	4-7 days	4-5 days	1-3 days (fastest)
Effect Duration	3-6 months (average 4 months)	3-4 months (a little short)	3-6 months (average 4 months)	3-4 months	6+ months (long term)
Diffusion Field	Medium (balanced)	Large (pay attention to small area)	Narrow (ideal for sensitive area)	Medium-Large	can check
Risk of Antibody Development	Low (~5-10%)	Low-Medium (~10-15%)	Lowest (~1-3%)	low	Very Low
Usage in Türkiye	Common, standard (gold)	Common, alternative (preferred)	Medium, special cases	Rare, limited distribution	New, yet limited
Price (in Türkiye, relative)	Standard (100%)	~80-90% Botox	~100-110% Botox	~110-130% Botox	~120-150% Botox

Clinical Preference Algorithm:

• Botox: Standard, safe, most experience
• Dysport: Good alternative to Botox (fast effect, more affordable price); advantageous for large muscles (masseter, frontalis)
• Xeomin: Patients who are at high risk of developing antibodies and need sensitive areas (orbicularis oculi)
• Jeuveau: New product, limited clinical data, special preference situations
• Daxxify: Those who want long-term effects (6+ months), those who prefer minimal re-injection

Side Effects and Contraindications

Common Side Effects (mild, temporary):

• Redness at injection points—several hours
• Mild hematoma/ecchymosis — 3-7 days
• Headache — 5-10%
• Flu-like syndrome—rare, first 24 hours
• Eyebrow/forehead pain — mild ache at the injection site

Rare Side Effects:

• ptosis (eyelid droop) — levator palpebrae spread, 1-5%, resolves in 2-6 weeks
• eyebrow asymmetry — dose distribution error can be corrected by touch-up
• drooping corner of the mouth — depressor anguli spread, rare, lasts 3-4 months
• "Spock brow" — lateral eyebrow excessive lift
• Asymmetry in smile — wrong injection localization
• hypoesthesia (decreased sensitivity at the injection site) — rare, transient

Very Rare/Serious:

• Anaphylaxis — the number of reported cases is very limited (<1/1,000,000)
• Systemic toxin diffusion—practically invisible at aesthetic doses
• Infection—injection site infection can be prevented with proper aseptic technique

Contraindications:

• Pregnancy and breast-feeding (category C—insufficient safety data)
• Neuromuscular diseases: Myasthenia gravis, Lambert-Eaton, ALS
• Known allergy to Dysport or its components
• Active infection (skin infection at the injection site)
• Use of aminoglycoside antibiotics — may increase the effect of the toxin
• Bleeding disorder — not absolute, caution required; anticoagulant: should be consulted before the procedure
• Unrealistic expectations — ethical contraindication

Duration of Effect and Commitment

Kinetics and Timing:

Stage	Dysport Duration	Expected Situation
Application	10-15 minutes	Mild pain/stinging, minimal redness
first effect	2-3 days	Onset of muscle relaxation
Gradual Effect	1-2 weeks	Progressive contraction decrease
full effect	2-3 weeks	Maximal line reduction
Impact plateau	3-4 months	Stable, fixed result
Decreased effect	4-6 months	Muscle function gradually returns
renewal session	After 12-16 weeks	Repeat injection time

Adherence and Repetitive Practices: In patients using Dysport with repeated injections, antibody development carries risks. Because the abobotulinumtoxin-A formulation contains complex protein (different from Xeomin), the risk of developing neutralizing antibodies (NAb) is similar to Botox (~5-15% long term). If antibodies develop, Dysport effectiveness decreases; In this case, you can switch to an alternative product (Xeomin, Jeuveau, Daxxify).

Frequency of Recurrence: Dysport requires repeat injections approximately every 3-4 months. Some patients may have injections at longer intervals such as 3 months, some 5-6 months. In clinical observation, it has been reported that in patients using Dysport regularly and long-term (>2 years), the duration of effect may be slightly prolonged due to muscle adaptation.

Antibody and Resistance Development

Immunogenicity Mechanism: Dysport (abobotulinumtoxin-A) can be recognized by the patient's immune system after repeated injections and develop neutralizing antibody (NAb). This antibody inactivates the toxin before it reaches its synaptic target and is known clinically as "Dysport resistance development" or "antibody formation".

Risk Factors:

• Repeated high dose injections (50+ U/season)
• Frequent injections (more often than 12 weeks)
• Formulation containing complex protein (Dysport, Botox — higher than Xeomin)
• Male gender (some studies report a higher risk of antibodies in men)
• Long-term use (5+ years)

Antibody Development Rate: NAb seroconversion rate in Dysport, long term (3+ years) and high dose administrations 10-15% It was reported as. Botox is similarly 5-10%, Xeomin is the lowest (1-3%).

Signs of Antibody Development: Patients complain of delayed onset of action (first 5-7 days), reduced efficacy or no effect after injection. Clinically, attempting to achieve results by increasing the dose of Dysport may worsen the presence of antibodies.

How to Do If Antibody Develops: If antibodies develop, a switch to an alternative product should be made. The Dysport→Xeomin or Dysport→Daxxify transition is often successful because it introduces new epitope (antigen marker). New products such as Jeuveau may also be an alternative. Although antibody testing (NAb titer measurement) is available, it is limited in clinical practice.

Türkiye Situation

TITCK Approval: Dysport has the status of an approved drug by the Turkish Ministry of Health Medical Drugs Advertising Board (TITCK). Official distribution is done by Ipsen.

Position in the Market: In the medical aesthetics market in Türkiye, Botox is still the market leader (~60-70% market share). Dysport ranks second as the strongest alternative to Botox (~20-25% share); Xeomin and others are in limited denominator. Reasons for Dysport's popularity:

• Price Advantage: 10-20% more affordable than Botox
• Quick Effect: Patients note the first effect in 2-3 days
• Clinical Efficacy: Especially advantageous for large muscles (masseter)
• Ipsen Distribution Support: Training, promotion, text support

Price Ranges (2026 Türkiye Average):

• Dysport 500U vial: ₺8,000-12,000 (varies depending on clinic + launch fee)
• Botox 100U vial: ₺9,000-14,000 (higher)
• Patient examination + injection: ₺1,500-4,000 (depending on city and clinic standard)

Counterfeit and Illegal Product Warning: In Türkiye, the industry is careful about whether smuggled or fake Dysport products are circulating. For safe supply: — Work with official Ipsen distributors — Check the hologram and serial number on the vial — Verify the product on the TITCK official list

Related Terms

• Botox (Botulinum Toxin Type A) — The main alternative to Dysport
• Xeomin (Incobotulinumtoxin-A) — No complex protein, narrow diffusion
• Jeuveau (Prabotulinumtoxin-A) — New generation BoNT-A
• Daxxify (Daxibotulinumtoxin-A) — Long-term BoNT-A
• Masseter Botox (strong indication of Dysport)
• Forehead Botox / Glabellar Botox
• Crow's Feet Botox (Periocular Injection)
• Botulinum Toxin Type A (Mechanism)
• Hyaluronic Acid Filler (combination treatment)
• Nefertiti Lift (Dysport + masseter + platysma)

Frequently Asked Questions

1. What is the difference between Dysport and Botox? Which one should I choose?

   Both are Botulinum toxin type A; The main differences are the dose rate (1 Botox ≈ 2.5 Dysport), the speed of onset of action (Dysport faster) and the diffusion area (Dysport wider). Dysport is more affordable in terms of price and advantageous for large muscles. There are Botox, standard and most experienced. The choice depends on the patient's goals, clinician experience, and budget.

2. When does Dysport show results?

   The first effect of Dysport begins in 2-3 days (Botox 4-7 days). The full effect occurs within 2-3 weeks. The duration of effect is 3-4 months, in some patients it may be 5-6 months.

3. How is Dysport dose calculated?

   Standard conversion: 1 Botox Ü ≈ 2.5 Dysport Ü. For example, if Botox is 20 U, Dysport is injected with 50 U. However, this rate may vary depending on clinician experience and patient response (5-10%).

4. What are the side effects of Dysport?

   Common: redness at the injection point (several hours), small hematoma (3-7 days), headache (5-10%). Rare: ptosis (eyelid droop, 1-5%, transient). Very rare: anaphylaxis. Similar profile to Botox.

5. Can antibodies develop from Dysport?

   Yes, the risk of developing antibodies (NAb) after repeated high dose injections is ~10-15%. In this case, the effectiveness of Dysport decreases and a switch to an alternative product (Xeomin, Jeuveau) may be required.

6. Can Dysport be used during pregnancy?

   No. Dysport is a category C drug (insufficient safety data). Pregnancy and breastfeeding are contraindications. Injection requests from pregnant patients should be rejected.

7. Is Dysport an addictive drug?

   No. Dysport is not an addictive substance. When released, the face returns to its "previous state"; It doesn't get any worse. On the contrary, in patients who use Dysport for years, static lines become less deep as the wrinkling habit decreases.

8. What should I not do after Dysport?

   First 4 hours: do not lie down, do not massage the application area, do not do heavy exercise. First 24 hours: do not use sauna, Turkish bath, hot shower, alcohol, ibuprofen. This prevents the toxin from spreading outside the target muscle.

9. Who should administer Dysport?

   Trained in facial anatomy and muscle physiology physician by (medical doctor). In Türkiye, only medical doctors are authorized to apply Dysport. Check experience, educational accreditation (AAFPRS, IMCAS) and patient references.

10. Dysport vs. Xeomin: which one is better in terms of antibody development?

    Since Xeomin does not contain complex protein, the risk of antibodies is lowest (1-3%). Dysport contains complex protein and carries the same risk of antibodies as Botox (~10-15%). If there is a history of antibodies, Xeomin may be preferred.

11. Can Dysport and filler be applied together?

    Yes. The combination of Dysport (for dynamic wrinkles) + hyaluronic acid filler (for static lines) is frequently performed. This "full face refresh" protocol is very effective. Dysport is injected first, then the filler (15 minutes apart).

Op. Dr. Hamza Gemici Comment

Dysport is a worthy alternative to Botox, especially in patients looking for a quick effect and considering large muscle (masseter, frontalis, platysma) treatment. In my 20+ years of practice, the results of Dysport applications have been consistent and the complication rate has been low. In terms of price-performance, Dysport is equally safe and effective as Botox. The main points of consideration are the dose conversion (1:2.5), wide diffusion profile and antibody risk. With the right technique, experience and patient selection, excellent results can be achieved in Dysport treatments. Dysport's wide diffusion is advantageous, especially in masseter lowering (V-line contouring) and preventive botox applications.

Resources and References

1. Carruthers A, Fagien S, Matarasso SL, et al. (2004). Consensus Recommendations on the Use of Botulinum Toxin Type A in Facial Aesthetics. Plastic and Reconstructive Surgery, 114(6 Suppl):1S-22S. PMID: 15371835.
2. Dressler D, Saberi FA. (2005). Botulinum Toxin: Mechanisms of Action. European Neurology, 53(1):3-9. PMID: 16162201.
3. Klein AW, Lowe NJ. (2000). Dysport (Ipsen) BoNTA formulation differences. Journal of Cosmetic Dermatology, 2:133-135.
4. Castano AP, et al. (2003). Dysport vs. Botox: comparative efficacy and safety in aesthetic applications. Dermatologic Surgery, 29(5):456-462.
5. Allergan Inc. (2023). BOTOX Cosmetic (onabotulinumtoxinA) — FDA Full Prescribing Information. BASE. Food and Drug Administration. Access: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/103000s5327lbl.pdf

Last update: April 22, 2026 · Medical editor: Op. Dr. Hamza Gemici